CGON_OUT_1 [2025-04-28 04:18:25 -0400] 5768 Bytes | 1599 tokens | Cum: 1599 tkns (19.99% of 8k)
==========================================================================

Booyah, my friends! It's already 4:18 AM on Mon Apr 28, 2025, and I've got my eyes locked on CG Oncology (CGON), pushing up to $27.50 from $21.52. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: CG Oncology (CGON)
IPO: 2024-01-25 (1 Year Ago)
Market Cap: $1,253,005,096
Shares Outstanding: 76,220,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Here’s a list of headlines for CG Oncology:

Apr-26-25 04:10PM - CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
Apr-24-25 08:00AM - CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
Apr-11-25 05:30AM - How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs
Apr-02-25 12:32PM - CG Oncology Looks Attractive At Current Prices (Rating Upgrade)
Mar-31-25 09:55AM - Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade
Mar-31-25 09:55AM 08:00AM - CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
Mar-31-25 09:55AM 05:54AM - Company News for Mar 31, 2025
Mar-28-25 07:00AM - CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
Mar-26-25 05:45PM - Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025?
Mar-24-25 08:00AM - Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
Mar-12-25 08:00AM - CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
Feb-26-25 08:00AM - CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Feb-25-25 09:49AM - Is CG Oncology, Inc. (CGON) An Oversold Biotech Stock to Buy Now?
Feb-23-25 01:29PM - Why CG Oncology, Inc. (CGON) is the Most Oversold Pharma Stock to Buy According to Analysts
Feb-20-25 12:19PM - Why CG Oncology (CGON) Is the Most Oversold Healthcare Stock to Buy Now
Jan-16-25 09:55AM - Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect?
Jan-03-25 10:00AM - How to Navigate the Stock and Bond Markets in 2025
Dec-16-24 04:05PM - CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Dec-12-24 08:19PM - CG Oncology Announces Pricing of Public Offering
Dec-11-24 06:17AM - CG Oncology Announces Proposed Public Offering
Dec-06-24 08:00AM - SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
Dec-06-24 08:00AM 07:10AM - CG Oncology announces data from Phase 3 BOND-003 trial

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-26T20:10:00Z - CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
B2 - 2025-03-12T12:00:00Z - CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
B3 - 2024-12-13T01:19:00Z - CG Oncology Announces Pricing of Public Offering
B4 - 2024-12-06T13:00:00Z - SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
B5 - 2024-08-30T12:00:00Z - CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
B6 - 2024-06-28T15:01:37Z - A Closer Look at 9 Analyst Recommendations For CG Oncology

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for CG Oncology (CGON).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

CGON_OUT_3 [2025-04-28 04:18:25 -0400] 1050 Bytes | 295 tokens | Cum: 1896 tkns (23.70% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/26/3068789/0/en/CG-Oncology-Announces-Best-in-Disease-Durability-Data-in-BOND-003-Cohort-C-and-Promising-Early-Signal-in-Cohort-P-for-Cretostimogene-Grenadenorepvec-at-the-American-Urological-Asso.htmlCG Oncology presented positive data on its investigational bladder cancer therapy cretostimogene grenadenorepvec, including a 42.3% complete response rate at 24 months and 90.5% high-grade recurrence-free survival at 3 and 9 months in separate patient cohorts.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CGON_OUT_5 [2025-04-28 04:18:26 -0400] 1007 Bytes | 302 tokens | Cum: 2200 tkns (27.50% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T04:04:28Z - CG Oncology announces Phase 3 BOND-003 data presented at AUA meeting...
A2 - 2025-04-26T20:22:05Z - CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signa...
A3 - 2025-04-26T20:10:03Z - CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signa...
A4 - 2025-04-26T20:22:06Z - CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signa...
A5 - 2025-04-26T20:22:05Z - CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signa...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CGON_OUT_7 [2025-04-28 04:18:27 -0400] 1181 Bytes | 328 tokens | Cum: 2530 tkns (31.62% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**CG Oncology announces Phase 3 BOND-003 data presented at AUA meeting**Date: 2025-04-28Source: {'uri': 'markets.businessinsider.com', 'dataType': 'news', 'title': 'Markets Insider'}URL: https://markets.businessinsider.com/news/stocks/cg-oncology-announces-phase-3-bond-003-data-presented-at-aua-meeting-1034630196CG Oncology (CGON) announced that cretostimogene grenadenorepvec monotherapy data was presented at the Practice-Changing, Paradigm-Shifting Clinical Trials in Urology Plenary Session at the 2025 American Urological Association, AUA, Annual Meeting, in Las Vegas, Nevada. The Phase 3 BOND-003 Cohort C study is in patients with high-risk non-muscle invasive bladder cancer, NMIBC, unresponsive to Bacillus Calmette Guerin, BCG, treatment with carcinoma in situ with or without Ta or T1 disease. The study reported 75.5% complete response at any time, with 34 confirmed CRs at 24 mont

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CGON_OUT_9 [2025-04-28 04:18:27 -0400] 616 Bytes | 176 tokens | Cum: 2708 tkns (33.85% of 8k)
==========================================================================

Showing A1 (chunk 2 of 2): hs and 9 patients pending their 24-month assessment as of the cutoff date of March 14, 2025. The 12- and 24-month CR rates are 50.7% and 42.3% by K-M estimation, respectively. Median duration of response, DOR, is 28 months and is ongoing. Notably, 97.3% of patients were free from progression to muscle invasive disease at 24 months.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CGON_OUT_11 [2025-04-28 04:18:28 -0400] 1102 Bytes | 286 tokens | Cum: 2996 tkns (37.45% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S6 - 2025-03-28 10-K Item 7 . Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our CONS financial statements and related notes inclu...

S7 - 2025-03-28 8-K Item 2.02 Results of Oper and Fin Cond.

On March 28, 2025, CG Oncology, Inc. issued a press release announcing its financial results for the year and quarter ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorpor...

S8 - 2025-03-24 8-K Item 7.01 Regulation FD Disclosure.

On March 24, 2025, CG Oncology, Inc. (the Company ) issued a press release entitled Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy The...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CGON_OUT_13 [2025-04-28 04:18:29 -0400] 1181 Bytes | 237 tokens | Cum: 3235 tkns (40.44% of 8k)
==========================================================================

Showing S6 (chunk 1 of 6): S6:
Item 7 . Managements Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties, including those described in the section titled Special Note Regarding Forward Looking Statements and Market Data. Our actual results and the timing of selected events could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those set forth under the section titled Risk factors in this Annual Report.

Overview

We are a late-stage clinical biopharmaceutical c

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CGON_OUT_15 [2025-04-28 04:18:30 -0400] 1181 Bytes | 259 tokens | Cum: 3496 tkns (43.70% of 8k)
==========================================================================

Showing S6 (chunk 2 of 6): ompany focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Our goal is to develop cretostimogene grenadenorepvec (cretostimogene), our product candidate, as an alternative to BCG in treating a broad range of bladder cancer indications. Cretostimogene, is in clinical development for the treatment of patients with high-risk NMIBC who are unresponsive to BCG therapy, the current standard-of-care for high-risk NMIBC. Given the limitations of currently approved therapies, the next course of treatment for these BCG-unresponsive patients is radical cystectomy, or the complete removal of the bladder, which is associated with significant social, functional and emotional burden. As such, there is a significant unmet need for effective treatments in these patients.

In anticipation of potential FDA approval, we are

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CGON_OUT_17 [2025-04-28 04:18:30 -0400] 1181 Bytes | 252 tokens | Cum: 3750 tkns (46.88% of 8k)
==========================================================================

Showing S6 (chunk 3 of 6): actively building our commercial operations, marketing, market access and patient access and field force capabilities. This includes pre-launch activities currently being executed, including scientific communication activities and engagements by our field medical organization. We are also implementing strategic initiatives to build seamless product distribution and patient support. Our efforts are focused on ensuring that we are fully prepared to launch and deliver cretostimogene to patients and healthcare providers, if approved. We are evaluating the safety and efficacy of cretostimogene, as a monotherapy, in BOND-003 Cohort C, our ongoing Phase 3 clinical trial in high-risk BCG-unresponsive NMIBC with CIS and with or without Ta/T1 disease. We have completed enrollment for this cohort and reported interim data at the American Urological Associations 2024 Annual Meeting in May 2024, and

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CGON_OUT_19 [2025-04-28 04:18:31 -0400] 1181 Bytes | 307 tokens | Cum: 4059 tkns (50.74% of 8k)
==========================================================================

Showing S6 (chunk 4 of 6): topline data at the 2024 SUO Annual Meeting in in December 2024, which was updated at the 40th Annual EAU Congress. We believe that this trial could serve as the basis for a BLA submission to the U.S. FDA, which we expect to initiate in the second half of 2025. Cretostimogene has received both Fast Track and Breakthrough Therapy designations from the FDA for the treatment of High-Risk BCG-unresponsive NMIBC with CIS with or without Ta or T1 tumors.

In April 2024, we initiated BOND-003 Cohort P, an exploratory study evaluating cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC with only Ta/T1 disease and expect to report topline data from this Cohort in the second half of 2025. In October 2024, we initiated CORE-008 Cohort A, our Phase 2 clinical trial in high-risk NMIBC patients who are nave to BCG treatment, including patients with CIS and with or without Ta/T1 disease and

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CGON_OUT_21 [2025-04-28 04:18:32 -0400] 1181 Bytes | 295 tokens | Cum: 4356 tkns (54.45% of 8k)
==========================================================================

Showing S6 (chunk 5 of 6): patients with only Ta/T1 disease. In March 2025, we expanded CORE-008 into the high-risk BCG-exposed population (Cohort B). We intend to add a third Cohort to CORE-008, evaluating cretostimogene in a combination therapy in the high-risk BCG-exposed population. We have recently completed and published the results for CORE-001, our Phase 2 clinical trial of cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients that have CIS. Additionally, in NMIBC that is not categorized as high-risk, we have launched our second Phase 3 clinical trial, PIVOT-006, evaluating adjuvant cretostimogene in intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT). We believe cretostimogene, if approved in intermediate-risk NMIBC, has the potential to serve as backbone therapy, thereby alleviating the current need to prioritize treatment recipi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CGON_OUT_23 [2025-04-28 04:18:33 -0400] 790 Bytes | 169 tokens | Cum: 4527 tkns (56.59% of 8k)
==========================================================================

Showing S6 (chunk 6 of 6): ents and ration administration of BCG given its significant market shortage.

Since our inception in 2010, we have focused substantially all of our resources on organizing and staffing our company, business planning, raising capital, establishing and maintaining our intellectual property portfolio, conducting research, preclinical studies, and clinical trials, establishing arrangements with third parties for the manufacture of cretostimogene, and providing general and administrative support for the...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CGON_OUT_25 [2025-04-28 04:18:40 -0400] 7487 Bytes | 2076 tokens | Cum: 6607 tkns (82.59% of 8k)
==========================================================================

This is our set of metrics for CG Oncology.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-------------------------+
| Volume: 1,651,275 | Perf Month: -15.71% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 878.21K | Perf Quarter: -27.35% | Short Float: 19.73% | ROE: -19.18% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 1.88 | Index: RUT | Short Ratio: 10.35 | ROI: -12.00% |
+---------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 52.55 | Market Cap: 1.70B | Short Interest: 9.09M | Sales Surprise: 330.18% |
+---------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 1.66 | Shs Outstand: 76.15M | Beta: 1.29 | EPS Surprise: -33.22% |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA20: 10.50% | Shs Float: 46.04M | Sales Q/Q: 45500.00% | P/E: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -7.64% | Inst Own: 67.15% | Sales past 5Y: 122.33% | Earnings: Apr 28 BMO |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -28.82% | Insider Own: 39.60% | Employees: 113 | |
+---------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: 8.38% | Insider Trans: -2.28% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading by CG Oncology officers or majority shareholders (if available).

Inside Trans: CG Oncology, Inc. (CGON) by Roche Corleen M. (CFO) on 2025-04-15
- Employee Stock Option (Right to Buy): 143907 shares at $0 (D)

Inside Trans: CG Oncology, Inc. (CGON) by Patterson Joshua F. (See Remarks) on 2025-04-15
- Employee Stock Option (Right to Buy): 119922 shares at $0 (D)

Inside Trans: CG Oncology, Inc. (CGON) by Kasturi Vijay (Chief Medical Officer) on 2025-04-15
- Employee Stock Option (Right to Buy): 203868 shares at $0 (D)

Inside Trans: CG Oncology, Inc. (CGON) by Bellete Ambaw (President and COO) on 2025-04-15
- Employee Stock Option (Right to Buy): 284816 shares at $0 (D)

Inside Trans: CG Oncology, Inc. (CGON) by Kuan Arthur (Chief Executive Officer) on 2025-04-15
- Employee Stock Option (Right to Buy): 527660 shares at $0 (D)

Inside Trans: CG Oncology, Inc. (CGON) by POST LEONARD E (Unknown Title) on 2025-03-17
- Common Stock: 1000 shares at $0.6 (D)
- Common Stock: 1000 shares at $28 (D) Footnote: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024.
- Director Stock Option (right to buy): 1000 shares at $0 (D)

Inside Trans: CG Oncology, Inc. (CGON) by POST LEONARD E (Unknown Title) on 2025-02-18
- Common Stock: 1000 shares at $0.6 (D)
- Common Stock: 1000 shares at $28.61 (D) Footnote: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024.
- Director Stock Option (right to buy): 1000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 1139000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -88039000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 22.37
Average Volume: 1508572.84
30-Day High: 24.49
30-Day Low: 15.59

[Detailed Financials: TTM 2024]
- Total Assets: $754,797,000.00
- Total Liabilities: $21,420,000.00
- Total Equity: $733,377,000.00
- Current Assets: $754,210,000.00
- Current Liabilities: $21,368,000.00

[Income Statement: TTM 2024]
- Revenue: $1,139,000.00
- Net Income: $-88,039,000.00
- Gross Profit: N/A
- Operating Income: $-114,666,000.00
- Earnings Per Share (EPS): -1.41

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $248,802,000.00

[Detailed Financials: FY 2024]
- Total Assets: $754,797,000.00
- Total Liabilities: $21,420,000.00
- Total Equity: $733,377,000.00
- Current Assets: $754,210,000.00
- Current Liabilities: $21,368,000.00

[Income Statement: FY 2024]
- Revenue: $1,139,000.00
- Net Income: $-88,039,000.00
- Gross Profit: N/A
- Operating Income: $-114,666,000.00
- Earnings Per Share (EPS): -1.41

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $248,802,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of CG Oncology (CGON).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about CG Oncology.

2) MARKET_SCORE[]
This conversation was initiated because CGON is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for CGON.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, CGON could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect CGON to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of CG Oncology.

11) ETHICAL_RATING[]
Rate CG Oncology’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of CG Oncology.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

CGON_IN_27 [2025-04-28 04:18:40 -0400] 126 Bytes | 29 tokens | Cum: 6830 tkns (85.38% of 8k)
==========================================================================

====================================
[2025-04-28 04:18:40] # Analysis Completed
Elapsed Time: 16.36 seconds